Some younger patients with B-cell acute lymphoblastic leukemia may be able to avoid total body irradiation conditioning prior ...

Comparing proteomics to genomics reveals essential insights into their contributions to systems biology and experimental ...

Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and ...

Avance Biosciences has opened a 75,000-square-foot biomanufacturing facility in Northwest Houston. The facility will support ...

Corporation (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical ...

The 2-year event-free survival (EFS) rate in the treatment arm was 76.3% (95% CI, 61.1%-86.1%), and the 2-year overall survival (OS) rate was 82.0% (95% CI, 67.1%-90.6%). These results showed that the ...

In the past twenty years, major technological advances in extracting and analyzing DNA have transformed the ability to ...

ORLANDO, Dec. 6, 2025) In a new trial , patients with B-acute lymphoblastic leukemia (B-ALL) who had no evidence of remaining cancer cells after ...

Emerging tests and treatment strategies guide more tailored approaches and ease the burden on patientsORLANDO, Fla., Dec. 6, ...

Genetron Holdings Ltd, a leading precision oncology platform in China also known as Genetron Health, announced on Tuesday ...

NITI Aayog hopes that by 2035, India’s homegrown quantum computing platforms may help accelerate drug discovery by simulating ...

Removing total body irradiation (TBI) from conditioning did not degrade efficacy in pediatric and young adult patients with B ...